Equity Overview
Price & Market Data
Price: $10.36
Daily Change: -$0.26 / 2.51%
Daily Range: $9.89 - $10.49
Market Cap: $693,961,024
Daily Volume: 82,412
Performance Metrics
1 Week: 4.23%
1 Month: 10.92%
3 Months: 50.58%
6 Months: 168.4%
1 Year: 69.28%
YTD: 14.73%
Company Details
Employees: 82
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.